Related Experiment Video
Updated: Feb 15, 2026

Transverse Aortic Constriction in Mice
Published on: April 21, 2010
SS31 therapy effectively protects the heart against transverse aortic constriction-induced hypertrophic
Hung-I Lu1, Fan-Yen Lee1, Christopher Glenn Wallace2
1Division of Thoracic and Cardiovascular Surgery, Department of Surgery, Kaohsiung Chang Gung Memorial Hospital and Chang Gung University College of MedicineKaohsiung 83301, Taiwan.
Insights
SS31 therapy effectively protected the heart from transverse aortic constriction-induced hypertrophic cardiomyopathy. This peptide treatment reduced cardiac damage, inflammation, and oxidative stress, preserving heart function in mice.
Area of Science:
- Cardiovascular Biology
- Pharmacology
- Mitochondrial Medicine
Background:
- Hypertrophic cardiomyopathy (HCM) is a significant cardiovascular disease.
- Transverse aortic constriction (TAC) is a common model for inducing cardiac hypertrophy and dysfunction.
- Mitochondrial dysfunction and oxidative stress play key roles in the pathogenesis of HCM.
Purpose of the Study:
- To investigate the protective effects of SS31 therapy against TAC-induced cardiac damage.
- To evaluate the impact of SS31 on cardiac function, cellular damage, and molecular pathways in a mouse model of HCM.
Main Methods:
- Adult male mice underwent TAC or sham surgery.
- Mice received SS31 treatment (2.0 mg/kg/day) starting 28 days post-TAC.
- Cardiac function, histology, and protein expression of inflammatory, apoptotic, fibrotic, and oxidative stress markers were assessed at 60 days.
Main Results:
- SS31 treatment significantly improved left ventricular ejection fraction and reduced cardiac hypertrophy compared to TAC alone.
- SS31 suppressed TAC-induced increases in apoptotic nuclei, inflammatory cell infiltration, oxidative stress biomarkers, and fibrosis.
- SS31 modulated key signaling pathways involved in inflammation, apoptosis, fibrosis, and mitochondrial damage.
Conclusions:
- SS31 therapy demonstrates significant cardioprotective effects against TAC-induced hypertrophic cardiomyopathy.
- SS31 mitigates cardiac damage by reducing inflammation, oxidative stress, apoptosis, and fibrosis.
- SS31 represents a promising therapeutic agent for managing HCM and related cardiovascular conditions.
Abstract:
This study tested the hypothesis that SS31 therapy could effectively protect the heart against transverse aortic constriction (TAC)-induced hypertrophic cardiomyopathy (HCM) damage. Adult-male B6 mice (n=36) were equally divided into sham-operated control (group 1), TAC only (group 2) and TAC+SS31 (group) (2.0 mg/kg/day by intra-peritoneal administration from day 28 after TAC induction) and euthanized by day 60. In vitro results showed that SS31 markedly suppressed angiotensin-II induced protein expressions of BNP/β-MHC, ATM, p-P38 and P53 and ATP damage in H9C2 cells, and protein expression of pro-collagen-I/CTGF in fibroblasts (all P<0.001). By day 60, left ventricular ejection fraction (LVEF) and sarcomere length were significantly lower in group 2 than groups 1 and 3, and significantly lower in group 3 than in group 1, whereas the LEVDd/LVESd and ratio of heart weight to tibial length showed an opposite pattern to LVEF (all P<0.0001). Microscopic findings of numbers of apoptotic nuclei, inflammatory (CD14+, F4/80+) and oxidative-stress (H2DCFDA+) biomarkers, disorganized score of endocardium, and fibrotic and collagen-deposition areas showed an opposite pattern to LVEF among the three groups (all P<0.0001). The protein expressions of inflammatory (PDGF/TNF-α/NF-κB/COX-2), oxidative-stress (NOX-1/NOX-2/oxidized protein), fibrotic (TGF-β/Smad3) apoptotic (cleaved-caspase-3/cleaved-PARP), pressure/volume overload (BNP/β-MHC), CTGF, mitochondrial-damaged (cytosolic cytochrome-C), p-ERK1/2, p-Akt and PI3K signaling showed an opposite pattern to LVEF among the three groups (all P<0.001). The protein expression of anti-oxidants (HO-1/Nrf2) were significantly progressively increased in groups 1 to 3 (all P<0.001). In conclusion, SS31 therapy effectively protected the heart against TAC-induced damage.
Related Concept Videos
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure VI: Adjunct Therapies
Cardiomyopathy II: Dilated Cardiomyopathy
Anatomy of the Heart
Cardiomyopathy IV: Restrictive Cardiomyopathy
Speed of a Transverse Wave
One of the key properties of any wave is the wave speed. Light...

